Telo Genomics Corp (TSE:TELO) has released an update.
Telo Genomics Corp. is conducting a clinical trial to assess the capability of its MRD assay in detecting minimal residual disease in multiple myeloma patients, with the aim of developing prognostic tests for the disease. Utilizing Adaptive Biotechnologies’ clonoSEQ assay technology, the study evaluates Telo’s assay sensitivity and seeks to establish its clinical utility. This clinical trial is part of the broader expansion of the MRD testing market, which is anticipated to grow significantly due to its role in personalized healthcare.
For further insights into TSE:TELO stock, check out TipRanks’ Stock Analysis page.
